Showing results (611-620 of 652) with videos related to

Sort By:
Pageof 66
Pediatric Blood & Cancer|March 13, 2026
Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High-Risk Neuroblastoma: A Multi-Institutional Retrospective StudyBenjamin J Lerman, Madeleine King, Rajen Mody, et al.
The Journal of Clinical Investigation|March 17, 2009
Glomerular type 1 angiotensin receptors augment kidney injury and inflammation in murine autoimmune nephritisSteven D Crowley, Matthew P Vasievich, Phillip Ruiz, et al.
Psycho-Oncology|October 28, 2020
Psychological, educational, and social late effects in adolescent survivors of Wilms tumor: A report from the Childhood Cancer Survivor StudyRebecca H Foster, Robert J Hayashi, Mingjuan Wang, et al.
Nature Communications|June 28, 2022
MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastomaLing Tao, Mahmoud A Mohammad, Giorgio Milazzo, et al.
Cancer|June 6, 2022
Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual diseaseAmi V Desai, Mark A Applebaum, Theodore G Karrison, et al.
Cancer Letters|May 18, 2019
Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signalingHui Li, Yang Yu, Yanling Zhao, et al.
Pediatric Blood & Cancer|March 24, 2025
Feasibility and Safety of Intratympanic Administration of Sustained-Exposure Dexamethasone Thermosensitive Gel (OTO-104) for Prevention of Cisplatin-Induced Hearing Loss in Children: A Multisite Phase 2 Randomized Clinical TrialDavid R Freyer, Timothy J D Ohlsen, Debra Don, et al.
Neurology|February 14, 2025
Montreal Cognitive Assessment vs the Mini-Mental State Examination as a Screening Tool for Patients With Genetic Frontotemporal DementiaLiset de Boer, Jackie M Poos, Esther Van Den Berg, et al.
Cancer|February 11, 2025
A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastomaSteven G DuBois, Chitose Ogawa, Lucas Moreno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2022
Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating FactorBenjamin J Lerman, Yimei Li, Cecilia Carlowicz, et al.
Pageof 66